Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report

2018 ◽  
Vol 25 (8) ◽  
pp. 2007-2009 ◽  
Author(s):  
Kevin Sullivan ◽  
Chung-Shien Lee
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Pemetrexed is an antifolate metabolite used to treat non-small cell lung cancer in the adjuvant and advanced setting. It is commonly known to cause rash, diarrhea, fatigue, mucositis, and myelosuppression. We report a case of a patient receiving adjuvant cisplatin and pemetrexed for non-small cell lung adenocarcinoma and experienced severe rhabdomyolysis.

scholarly journals An aggressive non-small cell lung cancer in nonsmokers: A case report of an unusual presentation of micropapillary lung adenocarcinoma

2017 ◽  
Vol 20 ◽  
pp. 125-128
Author(s):  
Aixa Dones Rodríguez ◽  
Kelvin Rivera Manzano ◽  
Ricardo Fernández González ◽  
José R. Adorno Fontánez ◽  
Ricardo A. Hernández ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Unusual Presentation ◽  
Small Cell Lung

68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report

2020 ◽  
pp. 107815522095124
Author(s):  
Ozgur Tanriverdi ◽  
Mehmet L Tarimer ◽  
Ceren D Pak ◽  
Selcuk Uylas ◽  
Ali Alkan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Mediastinal Lymph Node ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Free Survival

Introduction Lung cancer still ranks first among the most common and most lethal cancers today. The most common subtype is non-small cell lung cancer, and in this group, adenocarcinoma has the worst prognosis. EGFR, ROS1 and ALK-EML4 gene fusion mutations are common in non-small cell lung cancer. Case report A 62-year-old non-smoker patient applied in February 2014 for purulent sputum and pain in the chest. Computed tomography revealed a 39x33 mm mass in the right hilum, multiple parenchymal nodules in the bilateral lung and mediastinal multiple enlarged lymph nodes. The patient was admitted to the lung adenocarcinoma as a result of a biopsy from the mass in the hilum, and sarcoidosis was diagnosed by mediastinal lymph node biopsy. Management & outcome After 4 cycles of carboplatin-pemetrexed for the first line treatment, progression was detected. The patient did not have EGFR and ROS1 mutations. The patient with positive ALK fusion mutation started crizotinib treatment in July 2014. The patient's last response assessment was in March 2020, with 68-progression-free disease with crizotinib. No toxicity was observed except for Grade 1 weakness. No dose changes were made. The patient is still being followed up without brain metastasis under the treatment of crizotinib. Discussion In this article, we wanted to share our experience of crizotinib in a 68-months progression-free survival in a 62-years old non-smoking female patient with metastatic lung adenocarcinoma who is also diagnosed with sarcoidosis.

scholarly journals Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A Case report

2021 ◽  
pp. 101439
Author(s):  
Kyosuke Seguchi ◽  
Kei Nakashima ◽  
Toshiki Terao ◽  
Gaku Takeshita ◽  
Tatsuya Nagai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Febrile Neutropenia ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document